Gallic acid / LDH Cancer Research Results

GA, Gallic acid: Click to Expand ⟱
Features:
Phenolic acid found in gallnuts, sumac, witch hazel, tea leaves, oak bark. Has anitoxidant, antimicrobial and anti-obesity properties.
The GA derivatives include two types: ester and catechin derivatives. The most common ester derivatives of GA are alkyl esters, which are composed mainly of methyl gallate (MG), propyl gallate (PG), octyl gallate (OG), dodecyl gallate (DG), tetradecyl gallate (TG), and hexadecyl gallate (HG), and some of the main catechin derivatives are epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC), gallocatechin gallate (GCG), and epigallocatechin gallate (EGCG)

Gallic acid is a naturally occurring polyphenol found in a variety of plant-based foods. Some of the best dietary sources include:

Fruits:
Berries (strawberries, blackberries, blueberries)
Grapes, including red wine (grapes are rich in polyphenols)
Pomegranates and apples
Nuts and Seeds: Walnuts and almonds have been noted to contain GA in their skins
Herbs and Spices: Tea (especially green tea), Sumac and other spices
Other Plants: Gallnuts (from oak trees)

Pathways:
-ROS generation in tumor cells is frequently reported, Antioxidant behavior dominates in normal tissue models -Apoptosis Induction: Activating caspase cascades, Shifting Bax versus Bcl-2, MMP, cyt-c release -Cell Cycle Arrest: typ @ G1 or G2/M checkpoints.
-Anti-inflammatory Effects: inhibiting NF-κB
-reported Angiogenesis Inhibition:
-Modulation of Signaling Pathways: MAPK Pathway, PI3K/Akt Pathway Inhibition, p53 Pathway

Gallic acid exhibits a complex behavior with ROS in cancer cells, acting as both an antioxidant and a pro-oxidant depending on the context and its concentration:

Antioxidant Effects at Low Doses:
-At lower concentrations, gallic acid is typically characterized by its ability to scavenge free radicals, thus reducing oxidative stress.
This antioxidant property may help protect normal cells from DNA damage, reducing the risk of mutations that could lead to cancer.

Pro-oxidant Effects at High Doses: >50-100uM?
-Capable of biphasic redox behavior (antioxidant in normal cells, pro-oxidant in some tumor contexts) -At higher concentrations, GA can exert pro-oxidant effects, generating ROS within cancer cells. Elevated ROS levels can overwhelm the cellular antioxidant defenses of cancer cells, leading to oxidative stress, mitochondrial dysfunction, and ultimately cell death.

Oral bioavailability is moderate but subject to rapid conjugation (glucuronide/sulfate/methylated metabolites). Many cytotoxic in-vitro concentrations are in the 10–100 µM range, often higher than typical plasma levels after dietary intake.

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 ROS / Redox modulation (biphasic) ROS ↑ at higher concentrations (reported); mitochondrial stress ↑ ROS ↓; antioxidant protection P, R Redox destabilization (tumor) / buffering (normal) GA demonstrates dose-dependent redox behavior; pro-oxidant effects are most evident ≥50–100 µM in vitro.
2 Nrf2 / ARE antioxidant response Context-dependent; may support stress adaptation Nrf2 ↑; HO-1 ↑; GSH ↑ R, G Redox regulation Activation common in non-malignant oxidative stress models; tumor implications vary and may affect therapy sensitivity.
3 NF-κB inflammatory signaling NF-κB ↓; COX-2, IL-6, TNF-α ↓ (reported) Inflammation tone ↓ R, G Anti-inflammatory + anti-survival transcription One of the more consistent signaling findings across inflammatory and tumor models.
4 Intrinsic apoptosis (mitochondrial; p53-related) ΔΨm ↓; Bax ↑; Bcl-2 ↓; caspases ↑; cyt-c ↑ (reported) ↔ (limited activation) G Cell death execution Often ROS-mediated; p53 activation reported in several systems.
5 Cell-cycle checkpoints (G1 / G2-M) Cell-cycle arrest ↑ (Cyclin/CDK modulation) ↔ G Cytostasis Phase varies by tumor model; commonly G1 or G2/M.
6 PI3K → AKT (± mTOR) PI3K/AKT signaling ↓ (reported; model-dependent) ↔ R, G Growth/survival suppression Likely secondary to redox and inflammatory signaling modulation.
7 MAPK pathways (ERK / JNK / p38) JNK/p38 activation; ERK modulation (context-dependent) ↔ P, R, G Stress signaling reprogramming Often linked to ROS-mediated apoptosis pathways.
8 Angiogenesis signaling (VEGF) VEGF ↓ (reported in some models) ↔ G Anti-angiogenic modulation Evidence present but less consistent than redox and NF-κB effects.
9 Invasion / metastasis (MMPs / EMT) MMP2/MMP9 ↓; migration ↓ (reported) ↔ G Anti-invasive phenotype Likely downstream of NF-κB and MAPK modulation.
10 Bioavailability constraint (phase II metabolism) Rapid glucuronidation/sulfation; free GA low — — Translation constraint Plasma levels after dietary intake are generally below many in-vitro cytotoxic concentrations.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid redox interactions)
  • R: 30 min–3 hr (acute signaling and stress-response shifts)
  • G: >3 hr (gene-regulatory adaptation and phenotype outcomes)
LDH, Lactate Dehydrogenase: Click to Expand ⟱
Source:
Type:
LDH is a general term that refers to the enzyme that catalyzes the interconversion of lactate and pyruvate. LDH is a tetrameric enzyme, meaning it is composed of four subunits.
LDH refers to the enzyme as a whole, while LDHA specifically refers to the M subunit. Elevated LDHA levels are often associated with poor prognosis and aggressive tumor behavior, similar to elevated LDH levels.
leakage of LDH is a well-known indicator of cell membrane integrity and cell viability [35]. LDH leakage results from the breakdown of the plasma membrane and alterations in membrane permeability, and is widely used as a cytotoxicity endpoint.

However, it's worth noting that some studies have shown that LDHA is a more specific and sensitive biomarker for cancer than total LDH, as it is more closely associated with the Warburg effect and cancer metabolism.

Dysregulated LDH activity contributes significantly to cancer development, promoting the Warburg effect (Chen et al., 2007), which involves increased glucose uptake and lactate production, even in the presence of oxygen, to meet the energy demands of rapidly proliferating cancer cells (Warburg and Minami, 1923; Dai et al., 2016b). LDHA overexpression favors pyruvate to lactate conversion, leading to tumor microenvironment acidification and aiding cancer progression and metastasis.

Inhibitors:
Flavonoids, a group of polyphenols abundant in fruit, vegetables, and medicinal plants, function as LDH inhibitors.
LDH is used as a clinical biomarker for Synthetic liver function, nutrition

Tier A — Direct LDH Enzyme Inhibitors (Validated Catalytic Inhibition)

Rank Compound Type LDH Target Potency Level Primary Effect Notes
1 NCI-006 Research drug LDHA / LDHB High (in vivo active) Potent glycolysis suppression Modern benchmark LDH inhibitor used in metabolic oncology models.
2 (R)-GNE-140 Research drug LDHA (±LDHB) High (nM range reported) Lactate production ↓ Widely used experimental LDH inhibitor.
3 FX11 Research drug LDHA High (μM range) Metabolic crisis in LDHA-dependent tumors Classic LDHA inhibitor; often increases ROS secondary to metabolic stress.
4 Oxamate Tool compound LDH (pyruvate-competitive) Moderate (mM cellular use) Reduces lactate flux Classical LDH inhibitor; requires high concentrations in cells.
5 Gossypol Natural product derivative LDHA Moderate–High Glycolysis inhibition Also has other targets; safety considerations apply.
6 Galloflavin Natural compound LDH isoforms Moderate Lactate production ↓ One of the better-supported “natural-like” LDH inhibitors.

Tier B — Indirect LDH-Axis Modulators (Glycolysis / Lactate Reduction Without Confirmed Direct Catalytic Inhibition)

Rank Compound Mechanism Type LDH Claim Type Primary Axis Notes / Caution
1 Lonidamine MCT/MPC modulation Lactate axis inhibition Metabolic transport blockade Better classified as lactate/pyruvate transport modulator.
2 Stiripentol Repurposed drug LDH pathway modulation Metabolic axis modulation Emerging oncology interest; primarily neurological drug.
3 Quercetin Flavonoid Reported LDH inhibition (mixed evidence) NF-κB / PI3K modulation Often LDH-release confusion; direct enzymatic proof limited.
4 Ursolic acid Triterpenoid Reported LDH interaction Warburg modulation More credible as metabolic signaling modulator.
5 Fisetin Flavonoid Docking / indirect reports Apoptosis / survival signaling Enzyme inhibition not well validated.
6 Resveratrol Polyphenol Indirect glycolysis suppression AMPK / HIF-1α modulation Reduces lactate via upstream signaling.
7 Curcumin Polyphenol Indirect LDH expression modulation Inflammation + metabolic signaling Bioavailability limits translational strength.
8 Berberine Alkaloid Indirect metabolic modulation AMPK activation Closer to metformin-like metabolic pressure.
9 Honokiol Lignan Indirect glycolysis effects Survival pathway suppression Not validated as catalytic LDH inhibitor.
10 Silibinin Flavonolignan Mixed / indirect reports Inflammation + metabolic axis Often misclassified as LDH inhibitor.
11 Kaempferol Flavonoid Often LDH-release marker confusion Glucose transport / signaling Do not list as direct LDH inhibitor without enzyme data.
12 Oleanolic acid / Limonin / Allicin / Taurine Natural compounds Weak / indirect evidence General metabolic modulation Should not be categorized as true LDH inhibitors.

Tier A = Direct catalytic LDH inhibition (enzyme-level validation).
Tier B = Indirect lactate reduction or glycolytic modulation without strong catalytic inhibition evidence.
Important: LDH release assays (cell damage marker) are not proof of LDH enzymatic inhibition.



Scientific Papers found: Click to Expand⟱
987- GA,    Targeting Aerobic Glycolysis: Gallic Acid as Promising Anticancer Drug
- in-vitro, GBM, AMGM - in-vitro, Cerv, HeLa - in-vitro, BC, MCF-7
LDH↓, TumCG↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

LDH↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Clinical Biomarkers ⓘ

LDH↓, 1,  
Total Targets: 3

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: LDH, Lactate Dehydrogenase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:82  Target#:906  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page